Igor Splawski, PhD

Igor has three decades of experience in leading genetic discovery, as well as research and development of novel disease therapeutics.  He and his teams have brought over 20 compounds to clinical trials, including 11 currently in phase I - III trails.  

He has three decades of experience in leading genetic discovery, as well as research and development of novel disease therapeutics.  He and his teams have brought over 20 compounds to clinical trials, including 11 currently in phase I - III trails. 

Prior to joining Yarrow, Igor served as the Chief Scientific Officer of CureVac where he led the development of their mRNA technology and preclinical pipeline.

Dr. Splawski spent fifteen years at the Novartis Institutes for BioMedical Research (NIBR). While serving as the Executive Director and as a site head at the NIBR Biologics Center, he led a team of over 100 scientists that discovered and developed antibody and protein therapeutics.

Earlier in his career, Dr. Splawski served as an assistant professor at Harvard Medical School, where he identified new genes and mechanisms for cardiac arrhythmias and associated disorders, including cardiomyopathy, muscle disease, deafness, and autism. He has also held positions at Boston Children’s Hospital and Howard Hughes Medical Institute.

Igor received his PhD in Human Genetics from the University of Utah and MS in Biotechnology from Sofia University. He is an inventor on 30 granted patents and author of multiple publications in Cell, Science, NEJM, and Nature Journals.